Avastin Lung Cancer Reimbursement Will Be Case By Case, Genentech Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says it is too early to determine the extent of off-label use of Avastin in lung cancer. Genentech will present data on use of Avastin alone, as well as in combination with Tarceva, for the treatment of lung cancer at ASCO's annual meeting in May.
You may also be interested in...
Genentech Halts Avastin Trial Enrollment Due To GI Perforations
Phase II study of bevacizumab in platinum-refractory ovarian cancer patients demonstrated a higher rate of GI perforations than previously seen in studies of the oncologic.
Genentech Halts Avastin Trial Enrollment Due To GI Perforations
Phase II study of bevacizumab in platinum-refractory ovarian cancer patients demonstrated a higher rate of GI perforations than previously seen in studies of the oncologic.
Cancer Rx Reimbursement Made Smoother By Survival Benefit, Genentech Says
Survival data also helps oncologics avoid possible safety issues, CFO Ebersman said. Furthermore, if a product shows a survival benefit it creates an effective defensive strategy by establishing itself as standard of care.